Biofrontera Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Biofrontera Inc. (BFRI) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $0.89 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- Biofrontera Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $0.89.
- Biofrontera Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.99, a 66.55% decline year-over-year.
- Biofrontera Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $2.96.
- Biofrontera Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.00, a 27.01% decline from fiscal 2024.
- Biofrontera Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1.37, a 85.35% decline from fiscal 2023.
- Biofrontera Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $9.35, a 80.60% decline from fiscal 2022.
- Biofrontera Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $48.20.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $0.89 10-Q · filed 2026-08-13 | ||||
| 2026-03-31 | $0.89 10-Q · filed 2026-05-14 | ||||
| 2025-12-31 | $1.00 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | $1.00 10-Q · filed 2025-11-12 | ||||
| 2024-12-31 | $1.37 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | $1.38 10-Q · filed 2024-11-14 | ||||
| 2023-12-31 | $9.35 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $13.98 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | $13.98 10-Q · filed 2023-08-11 | ||||
| 2023-03-31 | $0.99 10-Q · filed 2023-05-12 | ||||
| 2022-12-31 | $48.20 10-K · filed 2024-03-15 | $2.41 10-K · filed 2023-03-13 | |||
| 2022-09-30 | $2.41 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | $2.62 10-Q · filed 2022-08-12 | ||||
| 2022-03-31 | $2.96 10-Q · filed 2022-05-13 | ||||
| 2021-12-31 | $95.40 8-K · filed 2023-10-03 | $4.77 10-K · filed 2022-04-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |